MDT-AP-1144
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 120
- os_event
- false
- age_years
- 8.9
- sex
- M
- new_clusters
- S2
- umap1_2d
- -0.973556352
- umap2_2d
- -9.321541139
- umap1_3d
- -3.463788081
- umap2_3d
- -1.646000608
- umap3_3d
- 5.930856817
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- MYC_TARGETS_V1+0.560
- G2M_CHECKPOINT+0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- ANGIOGENESIS+0.390
- MTORC1_SIGNALING+0.370
- OXIDATIVE_PHOSPHORYLATION+0.360
- INTERFERON_ALPHA_RESPONSE+0.330
- INFLAMMATORY_RESPONSE+0.320
- INTERFERON_GAMMA_RESPONSE+0.320
Top 10 suppressed
- HEME_METABOLISM-0.170
- KRAS_SIGNALING_DN-0.090
- PI3K_AKT_MTOR_SIGNALING-0.040
- APICAL_SURFACE-0.020
- ESTROGEN_RESPONSE_EARLY-0.020
- HEDGEHOG_SIGNALING-0.020
- TGF_BETA_SIGNALING+0.020
- MYOGENESIS+0.030
- UV_RESPONSE_UP+0.040
- ESTROGEN_RESPONSE_LATE+0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 40CDF034-0EBC-42A1-BBD8-492C1494086E | — | — | 0.898 |
| 2 | 8DA59514-8B25-493E-B226-818F2521B5D5 | — | — | 0.898 |
| 3 | E24D233D-71BD-4EC2-A671-375917F24E5C | — | — | 0.896 |
| 4 | 242A2775-52C6-4B3C-9317-A27C32C92A6E | — | — | 0.895 |
| 5 | MDT-AP-2822 | Med | Medulloblastoma | 0.888 |
| 6 | MDT-AP-0428 | Med | Medulloblastoma | 0.886 |
| 7 | 541FDA8B-9FAE-4346-A6FD-C56735C87920 | — | — | 0.886 |
| 8 | 8976C50F-B340-488D-B9C1-12CCAC780397 | — | — | 0.885 |
| 9 | BS_RSRPX3S8 | Med | Medulloblastoma | 0.884 |
| 10 | MDT-AP-1277 | Med | Medulloblastoma | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.560 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.370 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.320 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.260 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.260 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |